相关实验视频
Updated: Apr 12, 2026
08:28
Development of an In Vitro Ocular Platform to Test Contact Lenses
Published on: April 6, 2016
10.6K
凝嵌入的聚二甲基西洛干隐形眼镜用于眼部药物输送
Aravind Manjeri1, Sajan Daniel George1,2
1Department of Atomic and Molecular Physics, Manipal Academy of Higher Education, Manipal 576104, India.
ACS applied bio materials
|October 19, 2024
概括
这项研究提出了新的微流体隐形眼镜,用于改善眼部药物输送. 这些透镜具有嵌入水凝的微腔,使药物能够在需要时得到控制的释放,克服了传统眼药的局限性.
科学领域:
- 生物材料科学 生物材料科学
- 眼科医生 眼科 眼科
- 药物输送系统 药物输送系统
背景情况:
- 局部眼科药物输送面临着诸如低生物可用性和由于眼部生理限制而短暂的停留时间等挑战.
- 传统的方法,如眼滴和药膏在达到持续的药物度方面有效性有限.
- 需要新的方法来提高药物输送效率和患者对眼睛疾病的遵守性.
研究的目的:
- 开发和评估微流体隐形眼镜,嵌入水凝微腔,用于控制眼部药物输送.
- 为了证明一个响应眼睛pH值变化的按需药物释放机制.
- 克服传统局部眼科药物管理的局限性.
主要方法:
- 基于聚二甲基 (PDMS) 的隐形眼镜的制造与集成的水凝嵌入微腔使用自发的球形腔形成和同时的热固化.
- 在微腔中嵌入pH响应的水凝 (约. 150微米) 用于药物加载和受控释放.
- 研究药物释放动力学,基于通过微腔开口的扩散和水凝膨胀/脱水行为,以应对pH值变化.
主要成果:
- 成功制造PDMS隐形眼镜,其球形微空洞小于150微米.
- 从嵌入微腔体内的pH响应水凝中显示出受控的药物释放.
- 在正常眼睛pH值 (> 6) 下显示了最小的药物扩散,在降低pH值 (< 6) 下由于水凝脱水而加速释放.
结论:
- 带有水凝嵌入微腔的微流体隐形眼镜为按需眼部药物输送提供了一个有前途的平台.
- 水凝的pH响应性允许调节药物释放,解决当前局部眼科配方的局限性.
- 这项技术有可能通过提高药物的生物可用性和停留时间来改善各种眼部疾病的治疗结果.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
98
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
98
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
137
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
137
01:24Modified-Release Drug Delivery Systems: Site-Targeted
130
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
130
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
125
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
125
01:23Ophthalmic Drug Delivery Systems
245
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
245
01:21Intrauterine Drug Delivery Systems
149
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
149